Plain-English translation of NCT07760012 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called 68Ga-SorB PET/CT that uses a special tracer to find cancer cells in your body. Unlike standard cancer imaging scans, this medication targets a specific protein found on many types of cancer cells, which may help doctors spot tumors more accurately. The study will compare this new scan to the standard imaging scans you may already be having as part of your care.
Current cancer imaging scans sometimes show false positives — they light up in areas that aren't actually cancer, which can cause unnecessary worry and follow-up tests. This trial exists to see if the new treatment can be more precise and specifically target cancer cells while avoiding these false alarms.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the new imaging tracer through an IV, then undergo a PET/CT scan that takes pictures of your body to find cancer. Your participation involves one imaging visit and standard follow-up care with your doctor. If you're already scheduled for a routine cancer imaging scan as part of your treatment, this trial simply adds the new scan comparison to evaluate how well it works.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China